Crossmark

Next-generation Bruton’s tyrosine kinase inhibitors for chronic lymphocytic leukemia-associated membranoproliferative glomerulonephritis: a case report

Crossref DOI link: https://doi.org/10.1007/s00277-026-06730-w

Published Online: 2026-01-30

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chen, Li

Huang, Yuting

Xu, Jing

Huang, Sinian

Zhang, Qianying

Hua, Fanli

Pan, Xiaoxia

Mi, Jian-Qing
Funding

Funding for this research was provided by:

Innovative research team of high-level local universities in Shanghai
License Information

Text and Data Mining valid from 2026-01-30

Version of Record valid from 2026-01-30
More Information

Article History

Received: 24 November 2025

Accepted: 4 January 2026

First Online: 30 January 2026

Declarations

:

: This study was approved by the Ethics Committee of Ruijin Hospital in Shanghai (Approval number 2025–2) and conducted in accordance with the Declaration of Helsinki.

: Written informed consent was obtained from both patients for publication of this case report and any accompanying images.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below